DICE Therapeutics
potential best in class oral | DICE Therapeutics
Company
Deck Type
Deck date
March 2023
Slide
22 of 59
Related slides by other companies
Nuvalent
Investor Presentation
November 2023
preclinical is a brain penetrant her selective kinase inhibitor with potential to avoid adverse events related to inhibition | Nuvalent
Nuvalent
Investor Presentation
October 2022
preclinical is a brain penetrant her selective kinase inhibitor with potential to avoid adverse events related to inhibition | Nuvalent
Nuvalent
Investor Presentation
November 2023
preclinical is brain penetrant and alk selective with the potential to avoid related adverse events | Nuvalent
Erasca
Investor Presentation
August 2023
we believe eras is a potential best in class inhibitor that demonstrates high potency and selectivity against | Erasca
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights